1.Generation of monoclonal antibodies reactive to human interleukin 2(IL 2).
Youn Mun HA ; Jun Hyung LEE ; Seung Min YOO ; Jeong Je CHO ; Soon Tae HO ; Jae Kyung PARK ; Sang Yun NAM
Journal of the Korean Society for Microbiology 1993;28(4):313-319
No abstract available.
Antibodies, Monoclonal*
;
Humans*
;
Interleukins*
2.Cloning of the gene encoding human interleukin-2
Journal of Vietnamese Medicine 2005;310(5):26-30
Study on cloning of the gene encoding human interleukin-2 with gene produce method by RT-PCR. Results: cloned and determine order of gene fragment encoded IL-2 that having 333pp size (133 amino acids) from total RNA of human spleen by RT-PCR. The results of analysis order of cloned IL2 gem showed that there were 2 changes of single nucleotide (A36G, G54T) in comparison with that of the NP-000577 order registered in NCBI GenBank A36G and G54T. However, these changes did not make changes in amino acid sequence of the cloned II-2 gene
Interleukins
;
Human
;
Genes
3.Characteristics of interleukin 4-induced CD23 positive human B cells.
Korean Journal of Immunology 1992;14(1):9-14
No abstract available.
B-Lymphocytes*
;
Humans*
;
Interleukins*
4.Characteristics of interleukin 4-induced CD23 positive human B cells.
Korean Journal of Immunology 1992;14(1):9-14
No abstract available.
B-Lymphocytes*
;
Humans*
;
Interleukins*
5.The Cytokines: An Overview.
Yeungnam University Journal of Medicine 2010;27(1):1-7
Having an understanding of the properties of cytokines is essential for the immunologist, the researcher and the medical practitioner who need to understand immunologic diseases and immunological therapeutic approaches. Cytokines are redundant in their actions on target cells and promiscuous in their receptor reactions. (ED note: That is some cool use of English!) Moreover, many cells concomitantly produce several cytokines that have overlapping actions. Here this review provides conceptual framework to understand the intriguing aspects of the cytokine system.
Cytokines
;
Immune System Diseases
;
Interleukins
6.Expression of Tregs and IL-35 in Peripheral Blood of Patients with Newly Diagnosed Acute Myeloid Leukemia.
Pei-Xian YANG ; Pan WANG ; Lei FANG ; Qiong WANG
Journal of Experimental Hematology 2022;30(6):1688-1692
OBJECTIVE:
To explore the expression of regulatory T cells (Tregs) and interleukin-35 (IL-35) in peripheral blood of patients with newly diagnosed acute myeloid leukemia (AML).
METHODS:
Peripheral blood samples were collected from 33 newly diagnosed AML patients and 40 healthy volunteers. The levels of innate and adaptive immune cells and Tregs were detected by flow cytometry. Plasma IL-35 level was detected by enzyme-linked immunosorbent assay (ELISA). The expression levels of P35 and EBI3 mRNA were detected by RT-PCR. The correlation between the levels of Tregs and IL-35 was analyzed.
RESULTS:
The proportion of CD4+T cells, CD8+T cells, B cells and NK cells in peripheral blood of newly diagnosed AML patients were significantly lower than those of control group (P<0.05). The levels of Tregs, IL-35, and the expression of P35 mRNA and EBI3 mRNA were significantly higher than that of healthy control group (P<0.01). The Tregs level was positively correlated with plasma IL-35 level (r=0.668,P<0.01).
CONCLUSION
AML patients have a deficiency in immune function, which is characterized by the high levels of Tregs and IL-35 in peripheral blood, and it might be a new target for the treatment of AML.
Humans
;
Interleukins
;
Leukemia, Myeloid, Acute
7.A Study of Interleukin -8 in the Peritoneal Fluid of Patients with Endometriosis.
Han Bum LEE ; Tae Bum JUNG ; Joong Suk KIM ; Jung Bae KANG ; Hong Bae KIM ; Geun Young LEE ; Sung Won KANG
Korean Journal of Obstetrics and Gynecology 2000;43(8):1331-1335
No abstract available.
Ascitic Fluid*
;
Endometriosis*
;
Female
;
Humans
;
Interleukins*
8.Biological function of IL-33 and hepatic fibrosis.
Chinese Journal of Hepatology 2014;22(12):959-960
9.An experimental study on the enhanced cytolytic effects of natural killer cells by interleukin 2.
Hoon Bae JEON ; Sang Yong CHOI ; Young Chul KIM ; Bum Hwan KOO
Journal of the Korean Surgical Society 1993;45(3):314-323
No abstract available.
Interleukin-2*
;
Interleukins*
;
Killer Cells, Natural*
10.Interleukins in the treatment of melanoma.
Xinyuan XU ; Wei DAI ; Chunying LI
Chinese Medical Journal 2022;135(4):393-399
Interleukins (ILs) and associated cytokines serve as the means of communication for immune cells and non-immune cells. The use of ILs in harnessing the immune system to cancer treatment has been a promising approach. ILs not only nurture an environment enabling cancer growth but also simultaneously trigger a productive tumor-directed immune response. These properties of ILs are increasingly being explored as a strategy to improve the outcomes of cancer. Here, we describe recently innovative technological approaches that have been developed to improve the pharmacokinetics, safety, and efficacies of IL-2, 15, 10, and 18 in the treatment of melanoma. Furthermore, the combination of ILs and immune checkpoint inhibition may synergize to reshape the tumor environment, thus yielding better clinical benefits in the future.
Cytokines
;
Humans
;
Interleukins
;
Melanoma/drug therapy*